Charles River Expands Access to AAALAC-Accredited Space

Charles River Laboratories International, Inc., a company that provides products and services for the life sciences, plans to open Charles River Accelerator and Development Lab (CRADL) locations in Seattle and Philadelphia, expanding contract vivarium space for the biopharmaceutical industry.

CRADL Seattle is opening this September as Charles River’s most recent investment in Seattle, addressing the demand for more flexible vivarium space as well as on-demand in vivo study support services. CRADL’s first Seattle facility opened in 2021, in response to the city’s growing position as a key life sciences hub with significant start-up and entrepreneurial growth.

In October, CRADL Philadelphia will open in uCity Square to support Philadelphia’s growth as a life sciences biohub. Philadelphia has established itself as a leader in cell therapy, gene therapy, and gene editing. The CRADL facility will provide much needed research space to support the area’s continued growth.

By offering on-demand facilities, both emerging and established biopharmaceutical companies and research institutions can quickly start new in vivo studies for preclinical research stages. Each CRADL site provides flexible spaces, animal husbandry, and vivarium management.

“Both Seattle and Philadelphia are emerging as cities with significant biopharmaceutical communities. CRADL’s unique offering of contract vivarium space combined with Charles River’s extensive preclinical network, supports clients in starting projects quickly, without the costly burden of building infrastructure,” said Colin Dunn, corporate senior vice president, global research models & services, Charles River